![]() ![]() Individuals with atrial fibrillation often must balance the risk of stroke against the risk of excessive bleeding associated with taking anticoagulants. ![]() Patients are eligible for a WATCHMAN device if they have atrial fibrillation that is not caused by valve problems, face a moderate or high risk of stroke and cannot take anticoagulant medications. Food and Drug Administration (FDA) approved it in 2015 for reducing the risk of stroke in patients with the heart rhythm disorder atrial fibrillation. WATCHMAN is a device that blocks a portion of the heart known as the left atrial appendage to prevent blood clots from forming there, where they can exit the heart and cause strokes. between 2016-2018, revealed that procedural success and complications compared favorably with randomized trials as the use of WATCHMAN expanded across hundreds of hospitals. The study, which included data from nearly all procedures conducted in the U.S. ![]() Procedures to implant the WATCHMAN left atrial occlusion device had a high implant success rate and a low rate of in-hospital complications in an analysis of more than 38,000 procedures presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |